LivaNova (NASDAQ:LIVN) Updates FY25 Earnings Guidance

LivaNova (NASDAQ:LIVN) updated its FY25 earnings guidance on Tuesday. The company provided earnings per share guidance of $3.65-3.75 for the period, compared to the consensus earnings per share estimate of $3.66. The company issued revenue guidance of ~$1.316-1.329 billion, compared to the consensus revenue estimate of $1.33 billion. LivaNova also updated its FY 2025 guidance to 3.650-3.750 EPS.

LivaNova Price Performance

Shares of NASDAQ:LIVN traded down $8.91 during trading hours on Tuesday, hitting $40.59. 1,016,669 shares of the company’s stock traded hands, compared to its average volume of 489,086. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The company has a market cap of $2.20 billion, a price-to-earnings ratio of 96.95 and a beta of 1.00. LivaNova has a 52 week low of $40.77 and a 52 week high of $64.47. The company’s fifty day simple moving average is $47.94 and its two-hundred day simple moving average is $49.64.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Robert W. Baird lifted their target price on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Needham & Company LLC reaffirmed a “buy” rating and set a $75.00 price objective on shares of LivaNova in a research report on Tuesday, January 28th. StockNews.com upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 14th. Finally, Mizuho decreased their target price on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. One analyst has rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, LivaNova presently has a consensus rating of “Buy” and an average price target of $69.17.

Insider Transactions at LivaNova

In related news, Director Francesco Bianchi sold 1,250 shares of LivaNova stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the sale, the director now directly owns 7,522 shares of the company’s stock, valued at $383,546.78. This trade represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.27% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.